Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. The company was founded on August 23, 2004 and is headquartered in Givatayim, Israel.